^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Lovaxin C (axalimogene filolisbac)

i
Other names: ADXS11-001, Lm-LLO-E7, ADXS-HPV, ADXS-11-001, live attenuated listeria monocytogenes vaccine, Lm-Listeriolysin-O-fetal liver kinase-1, NSC-752718
Associations
Trials
Company:
Ayala Pharma
Drug class:
Immunostimulant, HPV-16 E7 protein inhibitor
Related drugs:
Associations
Trials
6ms
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer (clinicaltrials.gov)
P1, N=12, Completed, Advaxis, Inc. | Phase classification: P1/2 --> P1 | N=25 --> 12
Phase classification • Enrollment change
|
Lovaxin C (axalimogene filolisbac)
11ms
Enrollment change • Trial withdrawal
|
pemetrexed • Lovaxin C (axalimogene filolisbac)
over4years
[VIRTUAL] Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer (SGO-I 2020)
The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)
almost5years
Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer (SGO 2020)
The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)
almost5years
Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer (SGO 2020)
The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)